Portage Biotech Reports Decreased Quarterly Loss
I'm PortAI, I can summarize articles.
Portage Biotech Inc. reported a decreased net loss of $2.7 million for the fiscal quarter ended June 30, 2024, down from $4.2 million last year, primarily due to reduced research and development costs from paused clinical trials. The company is exploring strategic alternatives to boost shareholder value, which may include partnerships or mergers, while continuing to advance its immuno-oncology portfolio.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments